A Phase I/IIa, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of the Human Anti-CD38 Antibody MOR03087 as Monotherapy and in Combination With Standard Therapy in Subjects With Relapsed/Refractory Multiple Myeloma.

Trial Profile

A Phase I/IIa, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of the Human Anti-CD38 Antibody MOR03087 as Monotherapy and in Combination With Standard Therapy in Subjects With Relapsed/Refractory Multiple Myeloma.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs MOR 202 (Primary) ; Dexamethasone; Lenalidomide; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors MorphoSys
  • Most Recent Events

    • 02 Jun 2017 Interim results (n=79 data cut off: Jan 2017) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 21 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 06 Dec 2016 Interim results (n=66) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top